Sparks - Basilea Pharmaceutica

Basilea Pharmaceutica has secured an additional $13.3m in non-dilutive BARDA funding to support Phase III development of ceftibuten-ledaborbactam (CTB-LEDA) in complicated urinary tract infections, including pyelonephritis. This represents the third funding tranche under the $159m BARDA agreement signed in September 2025 (following prior $6m tranches in September 2025 and February 2026), which supports Phase III regulatory development and pre-commercial activities. Following this latest award, up to $133m remains available subject to predefined milestones. Phase III initiation is expected in Q127, with top-line data anticipated in early 2029. Management previously indicated that BARDA funding is expected to fully offset late-stage development costs, materially lowering Basilea’s cash burden and execution risk.

CTB-LEDA is being developed for multidrug-resistant Enterobacterales infections, an area with no approved oral beta-lactam/beta-lactamase inhibitor therapies and currently dominated by IV treatment options. We believe this supports CTB-LEDA’s positioning as a differentiated carbapenem-sparing oral step-down therapy, offering attractive antimicrobial stewardship and commercial potential. While GSK/Spero’s tebipenem HBr remains ahead in development and is currently under FDA review (PDUFA: 18 June 2026), we expect CTB-LEDA to occupy a distinct niche focused on carbapenem-sparing use.

With FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations in place, and late-stage development activities progressing, we see CTB-LEDA emerging as an increasingly important long-term value driver alongside Zevtera and fosmanogepix.